Table 2.

Characteristics of the patients whose staging was changed after PET scan or during surgery.

	PET Scan, N (%)	Surgery, N (%)
Staging/management changed	31 (10.9%)	36 (18.1%)
Pre-PET staging
Borderline resectable	18 (16.5%)	17 (33.3%)
Resectable	13 (7.4%)	19 (12.8%)
Gender
Male	22 (71%)	23 (63.9%)
Female	9 (29%)	13 (36.1%)
Site of metastases
Liver	20 (64.5%)	12 (33.3%)
Lung	4 (12.9%)	0
Lymph Node	6 (19.3%)	4 (11.1%)
Involvement of major blood vessels	0	10 (27.8%)
Peritoneum	0	9 (25%)
Other	1 (3.2%)	1 (2.8%)
Location of primary tumor
Head	25 (80.7%)	23 (63.9%)
Body/Tail	6 (19.3%)	13 (36.1%)
Tissue confirmation	19 (61.3%)	36 (100%)
CA 19-9 (X1000 U/ml), median (range)	0.5 (0–14.3)	0.4 (0–14.6)
SUV of pancreatic lesion, median (range)	7.7 (3.7–19.9)	6.9 (2.9–13.9)
Days between CT and PET scan, median (range)	13 (0–108)	3.5 (0–51)